Success Metrics

Clinical Success Rate
83.1%

Based on 98 completed trials

Completion Rate
83%(98/118)
Active Trials
18(10%)
Results Posted
45%(44 trials)
Terminated
20(11%)

Phase Distribution

Ph phase_1
22
12%
Ph phase_2
44
24%
Ph phase_4
38
21%
Ph phase_3
29
16%
Ph early_phase_1
8
4%
Ph not_applicable
34
19%

Phase Distribution

30

Early Stage

44

Mid Stage

67

Late Stage

Phase Distribution175 total trials
Early Phase 1First-in-human
8(4.6%)
Phase 1Safety & dosage
22(12.6%)
Phase 2Efficacy & side effects
44(25.1%)
Phase 3Large-scale testing
29(16.6%)
Phase 4Post-market surveillance
38(21.7%)
N/ANon-phased studies
34(19.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.4%

98 of 125 finished

Non-Completion Rate

21.6%

27 ended early

Currently Active

18

trials recruiting

Total Trials

180

all time

Status Distribution
Active(22)
Completed(98)
Terminated(27)
Other(33)

Detailed Status

Completed98
unknown31
Terminated20
Recruiting12
Withdrawn7
Active, not recruiting6

Development Timeline

Analytics

Development Status

Total Trials
180
Active
18
Success Rate
83.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 18 (4.6%)
Phase 122 (12.6%)
Phase 244 (25.1%)
Phase 329 (16.6%)
Phase 438 (21.7%)
N/A34 (19.4%)

Trials by Status

not_yet_recruiting32%
enrolling_by_invitation11%
terminated2011%
active_not_recruiting63%
suspended21%
unknown3117%
completed9854%
withdrawn74%
recruiting127%

Recent Activity

Clinical Trials (180)

Showing 20 of 180 trialsScroll for more
NCT07568574Not Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling By Invitation
NCT07265739Phase 2

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

Not Yet Recruiting
NCT03435939Early Phase 1

Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240

Completed
NCT05077800Phase 2

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Active Not Recruiting
NCT07300670Phase 1

The Effect of Losartan on Cephalexin

Recruiting
NCT05012631Phase 2

Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease

Recruiting
NCT06211335Phase 1

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

Recruiting
NCT03900793Phase 1

Losartan + Sunitinib in Treatment of Osteosarcoma

Recruiting
NCT07135687Phase 4

Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction

Not Yet Recruiting
NCT05619653Phase 3

Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19

Active Not Recruiting
NCT03563248Phase 2

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Active Not Recruiting
NCT01199978Phase 2

Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma

Active Not Recruiting
NCT06150560Phase 3

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

Recruiting
NCT04715568Phase 4

Secondhand Tobacco Smoke and Cardiovascular Disease

Recruiting
NCT03295734Phase 2

ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

Completed
NCT03519893

Bariatric Surgery and Pharmacokinetics of Losartan

Recruiting
NCT06364176Phase 2

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Recruiting
NCT06135493Phase 2

Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

Completed
NCT04106856Phase 1

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)

Active Not Recruiting
NCT02560805Phase 2

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

Suspended

Drug Details

Intervention Type
DRUG
Total Trials
180